GRAIL develops multi-cancer early detection tests based on blood analysis and genomic signals from circulating cell-free DNA. Its flagship product, Galleri, is designed to screen for signals associated with many cancer types from a single blood draw, aimed at earlier detection in asymptomatic adults. The company sits at the intersection of diagnostics, oncology and large-scale clinical validation rather than traditional single-cancer screening alone.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 31.8 | — | -106.2 | — |
| Q2 2025 | 35.5 | — | -114 | — |
| Q3 2025 | 36.2 | — | -89 | — |
| Q4 2025 | 43.6 | — | -99.2 | — |
| Q1 2026 | 40.8 | 28.1% | -93.2 | — |
| Q2 2026 | 44.7 | 25.7% | -110.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Waystar Holding Corp. (WAY), PriceSmart, Inc. (PSMT), Mirum Pharmaceuticals, Inc. (MIRM), Grifols, S.A. (GRFS), Riot Platforms, Inc. (RIOT), Cogent Biosciences, Inc. (COGT)